HRP20170794T1 - Izvedeni peptidi faktora viii za upotrebu u liječenju hemofilije a - Google Patents
Izvedeni peptidi faktora viii za upotrebu u liječenju hemofilije a Download PDFInfo
- Publication number
- HRP20170794T1 HRP20170794T1 HRP20170794TT HRP20170794T HRP20170794T1 HR P20170794 T1 HRP20170794 T1 HR P20170794T1 HR P20170794T T HRP20170794T T HR P20170794TT HR P20170794 T HRP20170794 T HR P20170794T HR P20170794 T1 HRP20170794 T1 HR P20170794T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- peptide
- preparation
- subject
- factor viii
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1220328.7A GB201220328D0 (en) | 2012-11-12 | 2012-11-12 | Peptides |
| GBGB1316660.8A GB201316660D0 (en) | 2013-09-19 | 2013-09-19 | Peptides |
| PCT/IB2013/060060 WO2014072958A1 (en) | 2012-11-12 | 2013-11-11 | Peptides |
| EP13795002.8A EP2917232B1 (en) | 2012-11-12 | 2013-11-11 | Factor viii-derived peptides for use in the treatment of haemophilia a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170794T1 true HRP20170794T1 (hr) | 2017-08-11 |
Family
ID=49627013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170794TT HRP20170794T1 (hr) | 2012-11-12 | 2013-11-11 | Izvedeni peptidi faktora viii za upotrebu u liječenju hemofilije a |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20150306192A1 (enExample) |
| EP (1) | EP2917232B1 (enExample) |
| JP (1) | JP6247696B2 (enExample) |
| KR (1) | KR102165486B1 (enExample) |
| CN (1) | CN104903347B (enExample) |
| AU (1) | AU2013343024B2 (enExample) |
| BR (1) | BR112015010625B1 (enExample) |
| CA (1) | CA2890835C (enExample) |
| CY (1) | CY1119164T1 (enExample) |
| DK (1) | DK2917232T3 (enExample) |
| EA (1) | EA036483B1 (enExample) |
| ES (1) | ES2626881T3 (enExample) |
| HR (1) | HRP20170794T1 (enExample) |
| HU (1) | HUE033586T2 (enExample) |
| IL (1) | IL238627B (enExample) |
| IN (1) | IN2015DN03814A (enExample) |
| LT (1) | LT2917232T (enExample) |
| MX (1) | MX350777B (enExample) |
| MY (1) | MY176708A (enExample) |
| NZ (1) | NZ708812A (enExample) |
| PH (1) | PH12015501033B1 (enExample) |
| PL (1) | PL2917232T3 (enExample) |
| PT (1) | PT2917232T (enExample) |
| RS (1) | RS56069B1 (enExample) |
| SG (1) | SG11201503657UA (enExample) |
| SI (1) | SI2917232T1 (enExample) |
| WO (1) | WO2014072958A1 (enExample) |
| ZA (1) | ZA201503127B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018206358B2 (en) | 2017-01-04 | 2021-05-27 | Worg Pharmaceuticals (Zhejiang) Co., Ltd. | S-Arrestin peptides and therapeutic uses thereof |
| EP3715374A1 (en) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Compound for the sequestration of undesirable antibodies in a patient |
| US11986536B2 (en) | 2019-03-23 | 2024-05-21 | Ablevia Biotech Gmbh | Compound for the sequestration of undesirable antibodies in a patient |
| GB201909774D0 (en) | 2019-07-08 | 2019-08-21 | Apitope Tech Bristol Limited | Method |
| WO2022063887A1 (en) | 2020-09-23 | 2022-03-31 | Ablevia Biotech Gmbh | Compound for increasing the efficacy of factor viii replacement therapy |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030062321A (ko) | 2000-08-21 | 2003-07-23 | 아피토프 테크놀러지 (브리스톨) 리미티드 | 펩티드 선별 방법 |
| US20040096456A1 (en) * | 2000-12-01 | 2004-05-20 | Conti-Fine Bianca M | Method to treat hemophilia |
| FR2842812A1 (fr) * | 2002-07-26 | 2004-01-30 | Pf Medicament | Procede de solubilisation de peptides hydrophobes et leur utilisation pour generer une reponse de type ctl antitumorale ou anti-infectueuse |
| JP2006188507A (ja) * | 2004-12-10 | 2006-07-20 | Tokyo Univ Of Agriculture & Technology | 蛋白質の溶解度向上方法 |
| EP1945797B1 (en) * | 2005-10-28 | 2012-05-30 | Boehringer Ingelheim International GmbH | Hepatitis c virus ns2/3 activity assay |
| GB0723712D0 (en) * | 2007-12-04 | 2008-01-16 | Apitope Technology Bristol Ltd | Peptides |
| GB0801513D0 (en) * | 2008-01-28 | 2008-03-05 | Circassia Ltd | Peptides from factor VIII |
| GB0908515D0 (en) * | 2009-05-18 | 2009-06-24 | Apitope Technology Bristol Ltd | Peptide |
| CA2780763A1 (en) * | 2009-11-13 | 2011-05-19 | Puget Sound Blood Center | Factor viii b cell epitope variants having reduced immunogenicity |
| PL3260132T3 (pl) * | 2010-10-27 | 2022-08-08 | Takeda Pharmaceutical Company Limited | Peptydy fviii do wywoływania tolerancji immunologicznej oraz immunodiagnostyki |
-
2013
- 2013-11-11 CN CN201380069078.2A patent/CN104903347B/zh not_active Expired - Fee Related
- 2013-11-11 LT LTEP13795002.8T patent/LT2917232T/lt unknown
- 2013-11-11 MX MX2015005973A patent/MX350777B/es active IP Right Grant
- 2013-11-11 BR BR112015010625-0A patent/BR112015010625B1/pt not_active IP Right Cessation
- 2013-11-11 DK DK13795002.8T patent/DK2917232T3/en active
- 2013-11-11 MY MYPI2015001224A patent/MY176708A/en unknown
- 2013-11-11 KR KR1020157012787A patent/KR102165486B1/ko not_active Expired - Fee Related
- 2013-11-11 RS RS20170542A patent/RS56069B1/sr unknown
- 2013-11-11 PL PL13795002T patent/PL2917232T3/pl unknown
- 2013-11-11 AU AU2013343024A patent/AU2013343024B2/en not_active Ceased
- 2013-11-11 JP JP2015541291A patent/JP6247696B2/ja not_active Expired - Fee Related
- 2013-11-11 EP EP13795002.8A patent/EP2917232B1/en active Active
- 2013-11-11 EA EA201590927A patent/EA036483B1/ru unknown
- 2013-11-11 PT PT137950028T patent/PT2917232T/pt unknown
- 2013-11-11 IN IN3814DEN2015 patent/IN2015DN03814A/en unknown
- 2013-11-11 SI SI201330663A patent/SI2917232T1/sl unknown
- 2013-11-11 HU HUE13795002A patent/HUE033586T2/hu unknown
- 2013-11-11 ES ES13795002.8T patent/ES2626881T3/es active Active
- 2013-11-11 HR HRP20170794TT patent/HRP20170794T1/hr unknown
- 2013-11-11 SG SG11201503657UA patent/SG11201503657UA/en unknown
- 2013-11-11 US US14/441,923 patent/US20150306192A1/en not_active Abandoned
- 2013-11-11 WO PCT/IB2013/060060 patent/WO2014072958A1/en not_active Ceased
- 2013-11-11 CA CA2890835A patent/CA2890835C/en active Active
- 2013-11-11 NZ NZ708812A patent/NZ708812A/en not_active IP Right Cessation
-
2015
- 2015-05-04 IL IL238627A patent/IL238627B/en active IP Right Grant
- 2015-05-07 ZA ZA2015/03127A patent/ZA201503127B/en unknown
- 2015-05-08 PH PH12015501033A patent/PH12015501033B1/en unknown
-
2017
- 2017-05-31 CY CY20171100568T patent/CY1119164T1/el unknown
-
2021
- 2021-04-23 US US17/239,251 patent/US20210346476A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
| EP3428182A3 (en) | Anti-inflammatory peptides and composition comprising the same | |
| EP3428181A3 (en) | Anti-inflammatory peptides and composition comprising the same | |
| HRP20140344T4 (hr) | Fviii peptidi i njihova uporaba u lijeäśenju hemofilije | |
| EP2528934A4 (en) | AROMATIC-CATIONIC PEPTIDES AND USES THEREOF | |
| MX2009004147A (es) | Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1. | |
| EA201200515A1 (ru) | Полипептиды и их применение | |
| GB201016733D0 (en) | Compounds and their use | |
| MX2016002937A (es) | Vacuna oncologica. | |
| GB201118201D0 (en) | Novel peptides | |
| MX385794B (es) | Péptidos inhibidores obtenidos del receptor desencadenante expresado en células mieloides de tipo 1 (trem-1) y transcrito similar a trem 1 (tlt-1) y usos de los mismos. | |
| NZ756128A (en) | Novel peptides and analogs for use in the treatment of oral mucositis | |
| IN2014DN09963A (enExample) | ||
| EA201590329A1 (ru) | Использование полученных из pedf полипептидов для стимуляции регенерации или артериогенеза в мышцах или сухожилиях | |
| HRP20141182T1 (hr) | Fviii-izvedeni peptidi i njihova upotreba za izazivanje tolerancije kod hemofiliäśara | |
| TR201906685T4 (tr) | Kristalin macitentan içeren farmasötik bileşim. | |
| EA201590601A1 (ru) | Применение pedf-производных полипептидов для лечения остеоартрита | |
| NZ703514A (en) | Fviii peptides for immune tolerance induction and immunodiagnostics | |
| BR112017014737A2 (pt) | formulação de peptídeos inibidores de mk2 | |
| WO2014039074A3 (en) | Therapeutic compositions and related methods | |
| EP2552462A4 (en) | CCN3 THERAPEUTIC PEPTIDES AND THEIR ANALOGS | |
| EP3026057A3 (en) | Compositions for prevention and treatment of neurodegenerative diseases | |
| MX2015002279A (es) | Peptido pntx(19) sintético, composición farmacéutica.y uso. | |
| JP2017517561A5 (enExample) | ||
| BR112015022730A2 (pt) | formulações de rfviii, método para conjugação covalente de rfviii com um polímero biocompatível e uso de rfviii no preparo de formulação de rfviii para tratamento de hemofilia a |